EGFR C797S is the principal acquired resistance mutation to osimertinib. Cis-configuratio...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-EGFR-C797S-NSCLC |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-NSCLC |
| Sources | SRC-CIVIC SRC-ESMO-NSCLC-METASTATIC-2024 SRC-NCCN-NSCLC-2025 |
Actionability Facts
| Biomarker | BIO-EGFR-MUTATION |
|---|---|
| Variant | C797S |
| Disease | DIS-NSCLC |
| ESCAT tier | IIB |
| Recommended combinations | amivantamab + carboplatin + pemetrexed (MARIPOSA-2), platinum-doublet chemotherapy, clinical trial of 4th-gen EGFR-TKI |
| Contraindicated monotherapy | osimertinib monotherapy (resistant), any current 3rd-gen EGFR-TKI alone |
| Evidence summary | EGFR C797S is the principal acquired resistance mutation to osimertinib. Cis-configuration with T790M renders all currently approved 3rd-gen EGFR-TKIs ineffective; trans-configuration may respond to combination 1st-gen + osimertinib. Investigational 4th-gen EGFR-TKIs (BLU-945, BBT-176) and amivantamab+chemo (MARIPOSA-2) are active options. |
Notes
OncoKB R2 (resistance, clinical evidence). Test allelic configuration (cis vs trans) when feasible — guides salvage choice. Trans-C797S/T790M retains sensitivity to gefitinib+osimertinib combo (case-series only).
Used By
No reverse references found in the YAML corpus.